Recon: Low Dose of Pfizer, Lilly Painkiller Misses Goals in Phase III Study

• Federal judge scolds Purdue, Endo and Mallinckrodt for stall tactics in opioids case (Fierce) (Law360-$)
• 'Old guard' generics players yield U.S. lead to Indian up-and-comers: analyst (Fierce)
• Judge rejects challenge of New York City's mandatory measles vaccination order (Reuters)
• Washington State Senate Passes Bill Removing Exemption For Measles Vaccine (NPR)
• Nationwide Recall of Popular Blood Pressure, Heart Drugs Expanded Over Cancer Concerns (NBC) (FDA)
• Consumer watchdog petitions FDA for black box warning on Amgen's Prolia (Fierce)
• Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study (Reuters) (STAT) (Endpoints) (Press)
• FDA Sends Warning Letters on Dietary Supplements (WSJ)
• BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models (Fierce)
• US launches four-state study to find ways to reduce opioid overdose deaths (Reuters) (NIH)
• Medicare payment rules hinder the fight against superbugs (STAT)
• Breaking Down 3 New Senate Bills Targeting Drug Prices (Law360-$)
• A Hippocratic Oath for Big Data (The Hill)

• Mereo’s shareholders back OncoMed takeover (PMLive)
• Lonza reports pharma strength as rest of business falters (BioPharmaDive)
• Australia and Canada Jointly Approve Breast Cancer Drug (Focus)
• Nearly 70 million people to be vaccinated during Vaccination Week of the Americas (PAHO)
• Chilean minister pushes back against pharma move to pressure its pricing policies (STAT)
• El Al Airline Warns of Measles After Flight Attendant Falls Into Coma (NYTimes)
• Roche throws in the towel on Tecentriq bladder, myeloma trials (Fierce)

• A Promising Anti-HIV Drug Poses A Dilemma (NPR) (Study)
• Many young cancer patients regret initial treatment decisions (Reuters)
• Two-wave U.S. flu season is now the longest in a decade (STAT)
• Bispecific Antibodies: FDA Drafts Guidance for Developers (Focus)
• DTC Drug Advertising: Study Finds Mixed Impact on Patients, Prescribers (Focus)
• Onpattro, Tegsedi Cardiac Imaging And Serum Biomarker Data Failed To Impress US FDA (Pink Sheet-$)
• BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models (Fierce)
• Chutes & Ladders—Gilman buckles in as Arrakis raises $75M, while Wotton takes over at Obsidian (Fierce)

• Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare (Press)

• 10 Deals That Shook up the Diagnostics Industry (MDDI)
• AngioDynamics to Divest its Fluid Management Portfolio (MDDI)
• CDRH Drafts Guidance on Quantitative Imaging (Focus)
• CDRH Draft Guidance Tackles Nitinol Devices (Focus)

• Genetic Testing Is On FTC's Radar (Law360-$)
• Talk Of Medicare For All Unnerving Investors (Forbes)
• Maine seeks to clarify limits on gifts and payments that pharma can give doctors (STAT)
• Wall Street, K Street step up criticism of 'Medicare for All' (Politico)
• Novartis Pharmaceuticals Corp. v. Par Pharmaceutical Inc. (D. Del. 2019) (Patent Docs)
• Doc Linked To Insys Denies New Charges In Patient's Death (Law360-$)
• Warning Causation Sinks Another Generic “Failure To Update” Claim (Drug & Device Law)
• If UnitedHealth Doesn’t Get Magellan, It Fits Anthem’s Services Strategy (Forbes)

• FDA Advisory Committee Calendar

• EU Regulatory Roundup: Commission Outlines How EU Data Protection Rules Affect Clinical Trial Sponsors (Focus)

• Indian generics contenders; Chi-Med's HK listing; Qilu Pharma explosion (Fierce)
• Asia Executives On The Move: New Daiichi CEO, WuXi CMO (Scrip-$)

• Is Dentistry Safe and Effective? (Marginal Revolution)
• This Genetic Mutation Makes People Feel Full — All the Time (NYTimes)
• Can Botox and Cosmetic Surgery Chill Our Relationships With Others? (NYTimes)
• Why Do Doctors Overtreat? For Many, It's What They're Trained To Do (NPR)